SXC-2023
NIDA-SXC-Ph1b-001
Phase 1 small_molecule completed
Quick answer
SXC-2023 for Cocaine Use Disorder is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BRIGHT MINDS BIOSCIENCES INC.
- Indication
- Cocaine Use Disorder
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed